Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA Negotiations Shift To 'Tiered' Fee Models

Executive Summary

Finance subgroup talks about new structure for generic drug user fee program that could mean bigger firms would pay more.

You may also be interested in...



GDUFA II: ANDAs, Not Facilities Will Govern Revenue

Since applications comprise most of the workload, they will be the focus in the next generic drug user fee cycle.

GDUFA II Will Include Small Business Relief, Priority ANDA Reviews

Generics industry and FDA have resolved remaining issues regarding financing of user fee program.

User Fees For FY 2017 Make Sponsors Happy, Manufacturers Sad

Several facility fees will increase next year as application fees drop.

Related Content

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel